{"pmid":32329930,"title":"Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement.","text":["Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement.","The current COVID-19 pandemic influences many areas of social life, medical treatments and the way allergy is performed. Allergen-specific immunotherapy (AIT) is one of the most important treatment options for IgE-mediated allergies and is based on immunological effects on the diseased patient.","Allergy","Klimek, Ludger","Jutel, Marek","Akdis, Cezmi","Bousquet, Jean","Akdis, Mubeccel","Bachert, Claus","Agache, Ioana","Ansotegui, Ignacio","Bedbrook, Anna","Bosnic-Anticevich, Sinthia","Canonica, Giorgio W","Chivato, Tomas","Cruz, Alvaro A","Czarlewski, Wiencyslawa","Giacco, Stefano Del","Du, Hui","Fonseca, Joao A","Gao, Yadong","Haahtela, Tari","Hoffmann-Sommergruber, Karin","Ivancevich, Juan-Carlos","Khaltaev, Nikolai","Knol, Edward F","Kuna, Piotr","Larenas-Linnemann, Desiree","Melen, Erik","Mullol, Joaquim","Naclerio, Robert","Ohta, Ken","Okamoto, Yoshitaka","O'Mahony, Liam","Onorato, Gabrielle L","Papadopoulos, Nikos G","Pawankar, Ruby","Pfaar, Oliver","Samolinski, Boleslaw","Schwarze, Jurgen","Toppila-Salmi, Sanna","Shamji, Mohamed H","Ventura, Maria Teresa","Valiulis, Arunas","Yorgancioglu, Arzu","Matricardi, Paolo","Zuberbier, Torsten","32329930"],"abstract":["The current COVID-19 pandemic influences many areas of social life, medical treatments and the way allergy is performed. Allergen-specific immunotherapy (AIT) is one of the most important treatment options for IgE-mediated allergies and is based on immunological effects on the diseased patient."],"journal":"Allergy","authors":["Klimek, Ludger","Jutel, Marek","Akdis, Cezmi","Bousquet, Jean","Akdis, Mubeccel","Bachert, Claus","Agache, Ioana","Ansotegui, Ignacio","Bedbrook, Anna","Bosnic-Anticevich, Sinthia","Canonica, Giorgio W","Chivato, Tomas","Cruz, Alvaro A","Czarlewski, Wiencyslawa","Giacco, Stefano Del","Du, Hui","Fonseca, Joao A","Gao, Yadong","Haahtela, Tari","Hoffmann-Sommergruber, Karin","Ivancevich, Juan-Carlos","Khaltaev, Nikolai","Knol, Edward F","Kuna, Piotr","Larenas-Linnemann, Desiree","Melen, Erik","Mullol, Joaquim","Naclerio, Robert","Ohta, Ken","Okamoto, Yoshitaka","O'Mahony, Liam","Onorato, Gabrielle L","Papadopoulos, Nikos G","Pawankar, Ruby","Pfaar, Oliver","Samolinski, Boleslaw","Schwarze, Jurgen","Toppila-Salmi, Sanna","Shamji, Mohamed H","Ventura, Maria Teresa","Valiulis, Arunas","Yorgancioglu, Arzu","Matricardi, Paolo","Zuberbier, Torsten"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329930","week":"202017|Apr 20 - Apr 26","doi":"10.1111/all.14336","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664996914917015552,"score":8.518259,"similar":[{"pmid":32224232,"title":"COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic.","text":["COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic.","In the event of a global infectious pandemic, drastic measures may be needed that limit or require adjustment of ambulatory allergy services. However, no rationale for how to prioritize service shut down and patient care exists. A consensus-based ad-hoc expert panel of allergy/immunology specialists from the United States and Canada developed a service and patient prioritization schematic to temporarily triage allergy/immunology services. Recommendations and feedback were developed iteratively, using an adapted modified Delphi methodology to achieve consensus. During the ongoing pandemic while social distancing is being encouraged, most allergy/immunology care could be postponed/delayed or handled through virtual care. With the exception of many patients with primary immunodeficiency, patients on venom immunotherapy, and patients with asthma of a certain severity, there is limited need for face-to-face visits under such conditions. These suggestions are intended to help provide a logical approach to quickly adjust service to mitigate risk to both medical staff and patients. Importantly, individual community circumstances may be unique and require contextual consideration. The decision to enact any of these measures rests with the judgment of each clinician and individual health care system. Pandemics are unanticipated, and enforced social distancing/quarantining is highly unusual. This expert panel consensus document offers a prioritization rational to help guide decision making when such situations arise and an allergist/immunologist is forced to reduce services or makes the decision on his or her own to do so.","J Allergy Clin Immunol Pract","Shaker, Marcus S","Oppenheimer, John","Grayson, Mitchell","Stukus, David","Hartog, Nicholas","Hsieh, Elena W Y","Rider, Nicholas","Dutmer, Cullen M","Vander Leek, Timothy K","Kim, Harold","Chan, Edmond S","Mack, Doug","Ellis, Anne K","Lang, David","Lieberman, Jay","Fleischer, David","Golden, David B K","Wallace, Dana","Portnoy, Jay","Mosnaim, Giselle","Greenhawt, Matthew","32224232"],"abstract":["In the event of a global infectious pandemic, drastic measures may be needed that limit or require adjustment of ambulatory allergy services. However, no rationale for how to prioritize service shut down and patient care exists. A consensus-based ad-hoc expert panel of allergy/immunology specialists from the United States and Canada developed a service and patient prioritization schematic to temporarily triage allergy/immunology services. Recommendations and feedback were developed iteratively, using an adapted modified Delphi methodology to achieve consensus. During the ongoing pandemic while social distancing is being encouraged, most allergy/immunology care could be postponed/delayed or handled through virtual care. With the exception of many patients with primary immunodeficiency, patients on venom immunotherapy, and patients with asthma of a certain severity, there is limited need for face-to-face visits under such conditions. These suggestions are intended to help provide a logical approach to quickly adjust service to mitigate risk to both medical staff and patients. Importantly, individual community circumstances may be unique and require contextual consideration. The decision to enact any of these measures rests with the judgment of each clinician and individual health care system. Pandemics are unanticipated, and enforced social distancing/quarantining is highly unusual. This expert panel consensus document offers a prioritization rational to help guide decision making when such situations arise and an allergist/immunologist is forced to reduce services or makes the decision on his or her own to do so."],"journal":"J Allergy Clin Immunol Pract","authors":["Shaker, Marcus S","Oppenheimer, John","Grayson, Mitchell","Stukus, David","Hartog, Nicholas","Hsieh, Elena W Y","Rider, Nicholas","Dutmer, Cullen M","Vander Leek, Timothy K","Kim, Harold","Chan, Edmond S","Mack, Doug","Ellis, Anne K","Lang, David","Lieberman, Jay","Fleischer, David","Golden, David B K","Wallace, Dana","Portnoy, Jay","Mosnaim, Giselle","Greenhawt, Matthew"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32224232","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.jaip.2020.03.012","keywords":["allergic rhinitis","allergy","allergy immunotherapy","angioedema","asthma","atopic dermatitis","covid-19","food allergy","primary immunodeficiency","sars-cov-2","urticaria","venom allergy"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["United States","Canada"],"countries":["Canada","United States"],"countries_codes":["CAN|Canada","USA|United States"],"_version_":1664640912819486720,"score":190.74318},{"pmid":32333915,"title":"Association of Respiratory Allergy, Asthma and Expression of the SARS-CoV-2 Receptor, ACE2.","text":["Association of Respiratory Allergy, Asthma and Expression of the SARS-CoV-2 Receptor, ACE2.","Underlying respiratory allergy and experimental allergen exposure reduce the expression of the SARS-CoV-2 receptor, ACE2, which could lead to reduced COVID-19 susceptibility.","J Allergy Clin Immunol","Jackson, Daniel J","Busse, William W","Bacharier, Leonard B","Kattan, Meyer","O'Connor, George T","Wood, Robert A","Visness, Cynthia M","Durham, Stephen R","Larson, David","Esnault, Stephane","Ober, Carole","Gergen, Peter J","Becker, Patrice","Togias, Alkis","Gern, James E","Altman, Mathew C","32333915"],"abstract":["Underlying respiratory allergy and experimental allergen exposure reduce the expression of the SARS-CoV-2 receptor, ACE2, which could lead to reduced COVID-19 susceptibility."],"journal":"J Allergy Clin Immunol","authors":["Jackson, Daniel J","Busse, William W","Bacharier, Leonard B","Kattan, Meyer","O'Connor, George T","Wood, Robert A","Visness, Cynthia M","Durham, Stephen R","Larson, David","Esnault, Stephane","Ober, Carole","Gergen, Peter J","Becker, Patrice","Togias, Alkis","Gern, James E","Altman, Mathew C"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333915","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jaci.2020.04.009","keywords":["ace2 expression","covid-19","sars-cov-2","allergic sensitization","asthma","receptor","respiratory allergy"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1665071049662791680,"score":162.61569},{"pmid":32272396,"pmcid":"PMC7128194","title":"The possible of immunotherapy for COVID-19: A systematic review.","text":["The possible of immunotherapy for COVID-19: A systematic review.","The novel coronavirus (2019-nCoV) is an emerging pathogen that was first described in late December 2019 and causes a severe respiratory infection in humans. Since the outbreak of COVID-19, international attention has raised to develop treatment and control options such as types of immunotherapies. The immunotherapy is an effective method for fighting against similar viral infections such as SARS-CoV, and MERS-CoV. These methods include several types of vaccines, monoclonal antibody candidates, and etc. This systematic review article was designed to evaluate the existing evidence and experience related to immunotherapy for 2019-nCoV. Web of Science (ISI), PubMed, and Scopus databases were used to search for suitable keywords such as 2019-nCoV, novel coronavirus, Immunotherapy, interleukin, vaccine and the related words for relevant publications up to 24.3.2020. The present systematic review was performed based on PRISMA protocol. Data extraction and quality valuation of articles were performed by two reviewers. 51 articles were the results of the search and based on the inclusions and exclusions criteria, 7 articles were included in the final review. As a conclusion of these studies demonstratedthat although no serious research has been done on this subject at the time of writing this article, similar studies on the related viruses showed notable results. So immunotherapy for this virus can also be a suitable option.","Int Immunopharmacol","AminJafari, Akram","Ghasemi, Sorayya","32272396"],"abstract":["The novel coronavirus (2019-nCoV) is an emerging pathogen that was first described in late December 2019 and causes a severe respiratory infection in humans. Since the outbreak of COVID-19, international attention has raised to develop treatment and control options such as types of immunotherapies. The immunotherapy is an effective method for fighting against similar viral infections such as SARS-CoV, and MERS-CoV. These methods include several types of vaccines, monoclonal antibody candidates, and etc. This systematic review article was designed to evaluate the existing evidence and experience related to immunotherapy for 2019-nCoV. Web of Science (ISI), PubMed, and Scopus databases were used to search for suitable keywords such as 2019-nCoV, novel coronavirus, Immunotherapy, interleukin, vaccine and the related words for relevant publications up to 24.3.2020. The present systematic review was performed based on PRISMA protocol. Data extraction and quality valuation of articles were performed by two reviewers. 51 articles were the results of the search and based on the inclusions and exclusions criteria, 7 articles were included in the final review. As a conclusion of these studies demonstratedthat although no serious research has been done on this subject at the time of writing this article, similar studies on the related viruses showed notable results. So immunotherapy for this virus can also be a suitable option."],"journal":"Int Immunopharmacol","authors":["AminJafari, Akram","Ghasemi, Sorayya"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32272396","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.intimp.2020.106455","keywords":["2019-ncov","covid-19","immunotherapy","interleukin","monoclonal antibody","vaccine"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664637315597729792,"score":150.39139},{"pmid":32304834,"title":"Special Article: Risk Communication During COVID-19.","text":["Special Article: Risk Communication During COVID-19.","During the unprecedented times caused by the novel coronavirus COVID-19, there is rapidly evolving information and guidance. However, a focus must also be on proper and effective risk communication. This is especially the case during pandemics that have high rates of infection, significant morbidity, lack of therapeutic measures, and rapid increases in cases, all of which apply to the current COVID-19 pandemic. A consequence of poor risk communication and heightened risk perception is hoarding behavior, which can lead to lack of medications and personal protective equipment. One potential way to ensure appropriate risk communication is utilizing social media channels, and ensuring an ongoing consistent media presence. Another important step is to include all stakeholders including members of the allergy community in broader public health messaging. As we continue to face unprecedented times in the allergy community, an understanding and appreciation of risk communication will be essential as we communicate with, and inform, our patients, and our colleagues, moving forward.","J Allergy Clin Immunol Pract","Abrams, Elissa M","Greenhawt, Matthew","32304834"],"abstract":["During the unprecedented times caused by the novel coronavirus COVID-19, there is rapidly evolving information and guidance. However, a focus must also be on proper and effective risk communication. This is especially the case during pandemics that have high rates of infection, significant morbidity, lack of therapeutic measures, and rapid increases in cases, all of which apply to the current COVID-19 pandemic. A consequence of poor risk communication and heightened risk perception is hoarding behavior, which can lead to lack of medications and personal protective equipment. One potential way to ensure appropriate risk communication is utilizing social media channels, and ensuring an ongoing consistent media presence. Another important step is to include all stakeholders including members of the allergy community in broader public health messaging. As we continue to face unprecedented times in the allergy community, an understanding and appreciation of risk communication will be essential as we communicate with, and inform, our patients, and our colleagues, moving forward."],"journal":"J Allergy Clin Immunol Pract","authors":["Abrams, Elissa M","Greenhawt, Matthew"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304834","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jaip.2020.04.012","keywords":["covid-19","sars-cov-2","health policy","pandemic planning","risk communication"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664632934637764609,"score":147.34462},{"pmid":32114747,"title":"[Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies].","text":["[Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies].","Corona Virus Disease 2019 (COVID-19) has seriously affected the treatment of patients and social stability. In the later stage of disease, some COVID-19 patients may develop into acute respiratory distress syndrome or even multiple organ failure. However, one of the most important mechanism underlying the deterioration of disease is cytokine storm. At present, some therapies such as interleukin-6 antibody blocker, stem cell therapy, and transfusion of convalescent plasma have been applied to counteract the cytokine storm and have made some progress. This article reviews the influences of cytokine storm syndrome on the COVID-19 and the corresponding immunotherapies to resist cytokine storm.","Zhonghua Shao Shang Za Zhi","Chen, C","Zhang, X R","Ju, Z Y","He, W F","32114747"],"abstract":["Corona Virus Disease 2019 (COVID-19) has seriously affected the treatment of patients and social stability. In the later stage of disease, some COVID-19 patients may develop into acute respiratory distress syndrome or even multiple organ failure. However, one of the most important mechanism underlying the deterioration of disease is cytokine storm. At present, some therapies such as interleukin-6 antibody blocker, stem cell therapy, and transfusion of convalescent plasma have been applied to counteract the cytokine storm and have made some progress. This article reviews the influences of cytokine storm syndrome on the COVID-19 and the corresponding immunotherapies to resist cytokine storm."],"journal":"Zhonghua Shao Shang Za Zhi","authors":["Chen, C","Zhang, X R","Ju, Z Y","He, W F"],"date":"2020-03-03T11:00:00Z","year":2020,"_id":"32114747","week":"202010|Mar 02 - Mar 08","doi":"10.3760/cma.j.cn501120-20200224-00088","keywords":["corona virus disease 2019","cytokine storm","cytokines","immune system","immunotherapy"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1664640875059216386,"score":132.43611}]}